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Abstract 
Corticosteroids are widely diffused drugs. An important side effect is the impairment of glycemic 
control both in patients with known diabetes and in normoglycemic ones potentially leading to 
steroid-induced diabetes mellitus (SIDM). 
In this review based on papers released on PubMed, MEDLINE, and EMBASE from January 2015 
to October 2017, we summarized and discussed main updates about the definition, the diagnosis, 
and the pathophysiology of steroid-induced hyperglycemia (SIH), with a look to new therapies. 
Main alterations responsible for the diabetogenic effect of corticosteroids are a negative impact on 
insulin sensitivity along with a derangement on insulin secretion, explaining the typical post-
prandial hyperglycemia linked to the promotion of gluconeogenesis. An early and precise diagnosis 
of SIH and/or SIDM is necessary, but current criteria do not seem sensible enough. As an 
afterthought, the treatment should be reasoned and tailored according to proposed glycemic 
thresholds and patient comorbidities, choosing between antidiabetic oral drugs and insulin, the latter 
being preferable among hospitalized patients. 
SIDM and SIH are frequent problems, but often underdiagnosed due to old diagnostic criteria. 
Dedicated guidelines universally shared are mandatory in order to harmonize the treatment of these 
conditions, thus overtaking single therapeutic strategies mostly arising from literature. 
 
Keywords: corticosteroids; steroid-induced hyperglycemia; diabetes; complications; therapeutic 
strategy; glycemic variability.  
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1. Introduction 
Corticosteroids are widely used with different purposes in several diseases. Just to remember a few, 
they are acutely administered in exacerbations of chronic obstructive pulmonary disease (COPD), 
gout, and chemotherapy as well as chronically in sarcoidosis, autoimmune diseases, and 
inflammatory bowel diseases. Alongside with their anti-inflammatory and immunosuppressive 
properties, glucocorticoids are burdened by several side effects [1], among which metabolic 
impairments represent the most important, such as the development of central adiposity, increase in 
triglyceride rich lipoproteins and non-esterified fatty acids (NEFA), hepatic steatosis, and 
breakdown of skeletal muscle mass [2]. Steroids might exacerbate hyperglycemia in patients with 
diabetes or facilitate the development in apparently healthy subjects of the so-called steroid-induced 
diabetes mellitus (SIDM), which represents an independent risk factor for other steroid therapy 
complications [3]. A deep understanding of hyperglycemic steroid-induced disorders is of 
paramount importance for several reasons. Firstly, these derangements are very often 
underdiagnosed and problems arising from diabetes itself may cause frequent or prolonged 
hospitalizations or emergency room visits. Secondly, the combination of steroidal treatment and 
diabetes can greatly increase the risk of infections due to both immunosuppression and lasting 
hyperglycemia. Finally, the control of even transient hyperglycemia has demonstrated to decrease 
mortality and complication rates [4]. 
In this review based on papers released on PubMed, MEDLINE, and EMBASE from January 2015 
to October 2017 (searched terms in combination: steroid-induced diabetes, steroid-induced 
hyperglycemia, glucocorticoid-induced hyperglycemia, hyperglycemia, corticosteroids; articles 
have been also retrieved through searches of reference lists and authors’ files, while abstracts have 
not been considered), we aimed at discussing and summarizing the main updates about the 
definition, the diagnosis, and the pathophysiology of steroid-induced hyperglycemia (SIH) and 
SIDM, with a look at new therapies for their management. With respect to previous reviews in the 
field, we focused on understanding more recent pathophysiological mechanisms of SIDM and 
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glucocorticoid-induced hyperglycemia (such as glycemic variability) and shedding some light on 
the therapeutic assessment, with a special interest to transient hyperglycemia and new drugs. We 
believe that this pathophysiological approach might be critical to improve clinical management of 
this frequent, but often underestimated condition. 
 
2. Definition, diagnosis, and risk factors 
The classical definition of SIDM refers to as an abnormal increase in blood glucose (BG) 
concentration during glucocorticoid use in patients with or without a previous history of diabetes 
[5]. Criteria for the diagnosis of diabetes by the American Diabetes Association, which have been 
accepted also by the Italian Society of Diabetology, rely on an 8-h fasting BG ≥126 mg/dL, 2-h 
post-75 g oral glucose tolerance test (OGTT) ≥200 mg/dL, a glycated hemoglobin value ≥6.5% or a 
random plasma BG value ≥200 mg/dL in patients with symptoms of hyperglycemia or 
hyperglycemic crisis [5, 6]. Anyway, two studies have underlined that patients with kidney and 
neurologic diseases under chronic steroidal agents showed post-prandial glucose values >200 
mg/dL and fasting BG values <100 mg/dL [7, 8]. Hence, it is now clear that SIDM is 
underdiagnosed since classical criteria are not so sensitive. For this reason, the diagnosis of SIDM 
has been reliably suggested on the basis of the 2-h post-prandial glucose value >200 mg/dL at any 
time of the day. In particular, the post-prandial glycemia after lunch appeared very sensitive, 
especially for the administration of a single morning dose of intermediate-acting glucocorticoids 
[9]. Another proposal includes the measurement of fasting and post-prandial glycemia in three 
consecutive days among subjects without diabetes treated with corticosteroids with a diagnostic 
threshold of 150 mg/dL [10], but does not gain popularity.  
As hyperglycemia is very common in the early posttransplant period due to immunosuppressive 
therapies, such as glucocorticoids, the definition of posttransplantation diabetes mellitus (PTDM) 
includes the presence of diabetes in the posttransplant period independently from the time of onset 
[11]. Glycated hemoglobin (HbA1c) has been considered for the diagnosis of PTDM with some 
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caution and the OGTT is not suitable due to its difficulty and the risk to underestimate the typical 
glucose increase mainly occurring in the late afternoon and in the evening [12], as recently 
confirmed by Porrini et al [13]. Hence, OGTT should be restricted to selected patients, for whom 
other tests failed. Several risk factors for the development of SIDM have been reported and are 
depicted in Table 1 [7, 14-18]. Interestingly, gender does not seem to seriously impact on SIDM 
development [19], while early withdrawal of steroidal drugs has been described as a protective 
factor [20, 21]. 
 
3. Epidemiology 
A real estimation of the risk of SIDM and SIH is very difficult due to different steroidal 
formulations, treatment duration, and dosing regimens. Moreover, in many studies only fasting 
glycemia is considered and this can lead to underestimate the real dimension of the disease. 
A meta-analysis by Liu et al including 13 studies has shown that the overall event rate of 
hyperglycemia among patients using glucocorticoid-related treatments was 32.3%, whereas 18.6% 
of patients developed SIDM [22]. Other studies found a nearly doubled risk of developing SIDM, 
ranging from 1.36 (95% confidence interval [CI] 1.10-1.69) [23] to 2.31 (95% CI 2.11-2.54) [24]. 
Interestingly, Gulliford et al reported no association between diabetes and injected, inhaled, or 
topical glucocorticoids or glucocorticoid eye drops, while the adjusted odds ratio (OR) for diabetes 
among patients treated with three or more oral glucocorticoid prescriptions was 1.36 (95% CI 1.10-
1.69), with an estimated population attributable risk of 2% [23]. Some years later, the use of inhaled 
corticosteroid (e.g. fluticasone) has been demonstrated to increase the rate of diabetes (rate ratio 
[RR] 1.34; 95% CI 1.29-1.39) and diabetes progression (RR 1.34; 95% CI 1.17-1.53) [25]. Besides, 
a direct correlation between the highest inhaled corticosteroid doses and increased incidence of 
SIDM has been described [25]. In the Reduction in the Use of Corticosteroids in Exacerbated 
COPD (REDUCE) randomized trial, a short-term (5 days) vs. a conventional (14 days) systemic 
glucocorticoid treatment has been tested in patients with COPD exacerbation and the prevalence of 
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new or worsening hyperglycemia at discharge across the whole cohort was nearly 60% (OR 0.98, 
95% CI 0.58-1.66) [26]. In a meta-analysis by Breakey et al, both oral and intravenous 
glucocorticoid therapy has been demonstrated to increase the risk of hyperglycemia in all subjects 
with known respiratory diseases [27]. 
Among patients with hematologic malignancies treated with glucocorticoids, the incidence of 
fasting plasma hyperglycemia after 8 weeks was 68.7%, whereas the incidence of frank diabetes or 
prediabetes was estimated at 34.3%. Indeed, post-prandial capillary hyperglycemia had an incidence 
of 15.6%, which added to diabetes and prediabetes led the incidence of SIDM among hematologic 
patients to nearly 50% [28]. Recently, in a cohort of patients with hematologic malignancies 
requiring frequent, high-dose corticosteroids, hyperglycemia has been described with a prevalence 
of 39% [29]. 
With concern to PTD, the incidence of SIDM differs according to the transplanted organ and the 
time occurring from transplantation. Kidney-transplanted patients showed a variable incidence of 
SIDM ranging from 15-30% after 1 year [30] to nearly 25% after 3 years [31], with a bimodal trend, 
within and over 3 months from transplantation [13]. PTD incidence is of 24% after 6 months from 
liver transplantation [32], of 15.7% after 2 years from heart transplantation [33], and increases up to 
approximately 60% after lung transplantation [34]. 
Finally, SIH is a very common finding among hospitalized patients without diabetes treated with 
high-dose steroid therapy [16]. Fong et al found that 86% of hospitalized patients showed at least 
one BG value ≥144 mg/dL and 70% a glycemic value ≥180 mg/dL, while mean glycemic values 
≥144 mg/dL have been found for 48% of subjects [35]. The study also confirmed data from Burt et 
al in prednisolone-treated COPD patients [36] indicating that hospital SIDM has a rapid onset 
within 2 days after the initiation of the therapy with a peak in the late afternoon [35]. Therefore, 
glucose monitoring across the first 48 hours is very important in order to identify the most patients 
developing hyperglycemia, stopping further testing in case of absence of hyperglycemia within the 
first 48 hours [37]. 
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Table 2 summarizes epidemiological data divided by different conditions according to main recent 
studies published within 2015 and 2018 [29, 38-54]. 
 
4. Pathophysiology of SIH 
Precise mechanisms accounting for glucocorticoid effects on glucose homeostasis are still 
incompletely understood and the greatest part of the current knowledge dates back to studies in rats 
and humans appeared in ‘60s and ‘70s [55]. 
Glucocorticoids perturb glucose metabolism by decreasing the pancreatic production and release of 
insulin in a dose-dependent manner, by reducing insulin sensitivity, and by increasing glucose 
production. Moreover, glucocorticoid effects are present also in adipose and muscle tissues (Figure 
1). 
 
4.1 Steroidal-related pancreatic β cell dysfunction and insulin-resistance 
Glucocorticoids have been demonstrated to impair β-cell function in healthy men, following both an 
acute and a 2-week exposure [56]. Steroid-induced pancreatic dysfunction in healthy men has been 
confirmed by van Raalte et al [57] and a pro-apoptotic effect of corticosteroids has also been 
postulated to contribute to β-cell failure [58]. Different studies in animal models have verified the 
impact of corticosteroids both intravenously and orally administered on insulin release, which is 
acutely abrogated in healthy subjects, showing stable levels of fasting insulin and high glucose 
levels [9]. In vitro studies using rodent islet cells have pointed out several mechanisms by which 
steroids can acutely alter insulin secretion: (i) reduced uptake and oxidation of various metabolites 
(including glucose); (ii) increased outward potassium currents limiting calcium influx; (iii) 
decreased efficacy of calcium ions on the insulin secretory process; (iv) alteration of the 
parasympathetic nervous system [2, 59]. In particular, prednisolone time-dependently inhibited 
glucose-stimulated insulin secretion in INS-1E cells and decreased both pancreatic-duodenal 
homeobox (PDX) 1 (a major regulator of the expression of a number of key β-cell genes [60]) and 
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insulin expression leading to a great reduction in cellular insulin content [61]. The role of 
prednisolone in inducing β-cell dysfunction has been further confirmed and extended as 
glucocorticoid-induced increase in fasting and post-prandial glucagon levels showed that 
prednisolone can also alter islet-cell functional balance, with a possible role for the autonomic 
nervous system imbalance, as abovementioned [62]. In addition, prednisolone treatment in healthy 
individuals has been found to dose-dependently impair insulin-stimulated capillary recruitment, 
which is strongly related to adverse metabolic effects, such as post-prandial glycemic excursions 
and reduced insulin sensitivity as well as high systolic blood pressure [63]. Moreover, 
glucocorticoid receptor-mediated impairment of endoplasmic reticulum pathways occurred 
concurrently with the upregulation of calpain 10 and the increased cleavage of caspase 3, 
underscoring that a prolonged exposure to prednisolone actively promotes apoptosis [61]. However, 
considering the use of glucocorticoids among patients with systemic inflammation, e.g. rheumatoid 
arthritis, it is conceivable that β-cell effects induced by inflammation can impair β-cell function 
under glucocorticoid stimuli [64]. A prolonged glucocorticoid exposure can enhance the previous 
mentioned pro-apoptotic effect, leading to final β-cell failure [65]. Similarly, but indirectly, β-cell 
failure can derive from elevated levels of triglycerides and NEFA, e.g. the so-called lipotoxicity 
[66]. Therefore, also in long-term glucocorticoid treatment, glucocorticoids are likely to induce both 
in vitro and in vivo hyperinsulinemia and hyperglycemia, ultimately leading to β-cell failure [2]. 
Anyway, due to ethical issues, effects in humans after prolonged exposure to glucocorticoids cannot 
be tested and studies are limited to maximally 14 days. Very recently, Fine et al have investigated 
some pathways via which glucocorticoids could modify β-cell signaling in order to assure insulin 
secretion [67]. To make a long story short, glucocorticoids, such as corticosterone and cortisol, can 
block voltage-dependent calcium channel function and calcium fluxes both in rodent and human β-
cells, but insulin secretion has been shown to remain unaffected by these alterations. Following this 
perturbation, a parallel upregulation of cyclic adenosine monophosphate (cAMP) as well as an 
increase in the amount of membrane-docked insulin secretory granules have been found, thus 
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preserving insulin secretion. As a further proof of it, lipotoxicity has been proven to limit 
glucocorticoid effects and similarly the complete deletion of 11β-hydroxysteroid dehydrogenase 
type 1 – reducing cortisone to the active hormone cortisol – normalized calcium and cAMP signals. 
Hence, the study by Fine et al has identified an enzymatically amplified feedback loop by which 
glucocorticoids promote cAMP upregulation maintaining insulin secretion unaltered in spite of 
ionic impairment and whose failure can partly explain the diabetogenic effect of glucocorticoid 
excess, such as that of prolonged systemic administration of steroidal therapy, typically coupled 
with impaired lipid metabolism [67]. 
Among different steps in the insulin signaling within cells, the binding between insulin and its 
receptor (IR) is important because it promotes an increased kinase activity and tyrosine 
phosphorylation of many downstream signaling molecules, such as insulin receptor substrate 1 
(IRS-1) through IRS-4. These molecules can trigger the phosphatidylinositol 3-kinase (PI3K) and 
mitogen-activated protein kinase (MAPK) pathways, leading to various downstream effects, all 
associated in particular with proliferative effects of insulin [68]. In skeletal muscle, glucocorticoids 
cause insulin resistance by a reduced transcription of IRS-1 and an increased transcription of the 
protein tyrosine phosphatase type 1B (PTP1B) and the p38MAPK [69], the latter being increased in 
liver, too [70]. Glucocorticoids can decrease IRS-1 and IRS-2 levels in fat [71], while a decreased 
phosphorylation of IR and IRS-1 have been demonstrated in the liver in response to glucocorticoids 
[72]. In 2007, the contribution of the bone to the insulin resistance induced by glucocorticoids has 
been firstly postulated. Lee et al demonstrated a role for osteocalcin in insulin resistance in 
knockout mice developing glucose intolerance and insulin resistance [73]. Proposed mechanisms 
for these alterations were: (i) a decreased pancreatic β-cell mass, responsible for hypoinsulinemia 
and (ii) a low adiponectin levels causing insulin resistance. Later, the disruption of the IR in 
osteoblasts was demonstrated to reduce osteocalcin levels and lead to similar metabolic changes 
[74]. As a confirmation, when osteocalcin was infused, a reduction in insulin resistance and an 
increase in glucose-driven insulin release were proven [75]. In 2012, Brennan-Speranza et al, by 
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using transgenic mice (Col2.3-11β-hydroxysteroid dehydrogenase type 2), surprisingly revealed a 
protection from obesity, hyperlipidemia, and insulin resistance usually associated with steroid 
agents. These transgenic mice did not increase neither in body weight nor in triglyceride levels and 
did not develop abnormalities in glucose metabolism after 4 weeks of treatment with corticosterone. 
These results have been confirmed also after expressing osteocalcin in mice livers in vivo [76]. 
 
4.2 Steroid-induced gluconeogenesis, glycogenolysis, and fatty acid catabolism 
Corticosteroids are strictly involved in the hepatic metabolism of glucose, thus increasing 
gluconeogenesis via the expression of different genes, such as phosphoenolpyruvate carboxykinase 
and glucose-6-phosphatase (Figure 1) [77, 78]. Moreover, corticosteroids can indirectly increase 
glucose production by limiting the metabolic actions of insulin [79] as well as they increase the 
quantity of substrates for hepatic gluconeogenesis via their actions on muscles and adipose tissue. 
In skeletal muscles, corticosteroids stimulate protein degradation and reduce protein synthesis, 
resulting in high levels of amino acids and progressive muscle atrophy (the so-called steroid 
myopathy) (Figure 1) [80, 81] and contribute to the reduced glucose uptake and the increased 
glycogenolysis (Figure 2) [82]. With regard to reduced glucose uptake in muscle and adipose 
tissues, the main mechanism resides in the inhibition of the glucose transporter type 4 (Figure 2) 
[83]. In adipose tissue, steroids are responsible for increased lipolysis and subsequent accumulation 
of NEFA, which interfere with insulin-induced glucose uptake [84]. Following prednisolone 
treatment, an increase in plasma concentrations of resistin has been described and linked to 
impaired microvascular function (Figure 1) [63]. As the same, adiponectin, usually promoting 
insulin sensitivity in tissues, is suppressed by glucocorticoid treatment, appearing as another actor 
in the steroid-induced insulin resistance [85]. Apart from the ability of corticosteroids to increase 
counter regulatory hormone levels [62], an important role for the steroid-related increase in the 
endogenous production of glucose has been hypothesized for the nuclear receptor peroxisome 
proliferator-activated receptor α in knockout mice [86], with the autonomic nervous system 
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accounting for a crucial role. Dexamethasone has been found to reduce the expression and 
phosphorylation of the IRS-1, PI3K, and protein kinase B (PKB)/Akt both in L6 skeletal muscle 
cells and in rat skeletal muscle (Figure 2) [87, 88]. A reduced insulin sensitivity can reside in 
corticosteroid-induced changes in protein and lipid metabolism, too [89]. 
The effects of corticosteroids are also linked to their pharmacodynamics, which actually has been 
evaluated only in healthy volunteers. Insulin resistance is mainly post-prandial developing within 
nearly 4 hours [90], but the variability of BG is strictly linked to dose, route of delivery, type of 
steroidal drug and its half-life, as illustrated in Table 3. For intermediate-acting steroids, such as 
prednisone, a single morning dose will cause hyperglycemia especially after lunch and in the late 
afternoon, with negligible effects on fasting glycemia. For long-acting corticosteroids, such as 
dexamethasone, the effect on glycemia will last for more than 24 hours and a slight decrease after 
an overnight fast might be present. Differently, for intra-articular steroidal drugs, such as 
triamcinolone, the peak of action can be from 2 to 24 hours after the administration and last until 5 
days later. 
In light of what described in the present chapter, new studies investigating metabolic effects of 
glucocorticoids are strongly needed. To date, the most knowledge relies on old data dating back to 
nearly fifty years, whilst in last decades many progresses have been done. Acquisitions concerning 
new mechanisms of actions of corticosteroids are now described in literature and pointed out as 
major contributors for the pathogenesis of diabetes and the development of its complications, such 
as epigenetics, just to cite one [91]. 
 
4.3 Glycemic variability during glucocorticoid therapy 
Since glycemic variability is highly debated for its potential role in the development of diabetic 
complications, glucocorticoid therapy represents a powerful trigger for glycemic excursions. This 
aspect has been investigated by van Hooijdonk et al among critically-ill patients administered with 
hydrocortisone boluses in the setting of the intensive care unit [92]. Authors concluded that bolus 
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infusion of hydrocortisone was associated with a higher glycemic and insulin rate variability across 
all Acute Physiology and Chronic Health Evaluation (APACHE) II score, irrespective of potential 
confounders, such as type of admission, body mass index, and age as well as a previous diagnosis 
of diabetes. Interestingly, glycemic variability was found to a lesser extent for more severely ill 
patients [92], thus confirming the pivotal role of the sympathetic nervous system in the glycemic 
homeostasis. Anyway, measures of glycemic variability have been made by two basic tools, such 
standard deviation and glycemic lability index, and results should be considered with some caution. 
Glycemic excursions during glucocorticoid therapy are typically influenced by pharmacodynamic 
and pharmacokinetic properties, with the typical peak of BG concentration in the later part of the 
day and a normalization of BG values in the morning for those taking short- or intermediate-acting 
glucocorticoids. Anyway, in contrast with type 2 diabetes, glycemic variability in patients with SIH 
or SIDM is likely to be affected by insulin resistance. The study by Weber-Carstens et al did 
demonstrate this aspect by showing that among patients administered with 50 mg of hydrocortisone, 
the ratio of caloric intake and insulin dosage did not change during the study period [93], so that BG 
increase reflected the reduced insulin sensitivity, which is a known pathophysiological mechanism 
of SIH and SIDM, as already discussed. Moreover, experimental and clinical data fret over high BG 
values suggesting a stringent control of SIH for hospitalized patients, as confirmed in critically ill 
patients, whose survival was linked to lower BG with respect to non-survivors [94]. Indeed, both 
mean and standard deviation of BG were significantly associated with intensive care unit mortality 
(OR 1.23 and 1.27, p <0.001, respectively) and in-hospital mortality (OR 1.21 and 1.18, p <0.001 
and p=0.013, respectively) [94], thus corroborating the concept that a decrease in glycemic 
variability might represent a promising therapeutic target in order to ensure a better prognosis, 
especially among critically ill patients. Anyway, future studies are advised to include some more 
complex indicators of glycemic variability as the mere standard deviation may not encompass all 
glycemic variations around abnormal high BG values and especially between abnormal high and 
low BG values, which could be more harmful for critically ill patients. As well, further 
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investigations evaluating new potential pathophysiological mechanisms and better therapeutic 
strategies (continuous vs. bolus insulin regimens) are warranted. In this view, even though not 
feasible for critically ill patients, dipeptidyl peptidase (DPP)-4 inhibitors could represent a 
promising therapeutic weapon when adopting a pathophysiological approach in non-critically ill 
patients [94]. 
 
5. Therapeutic management 
As for diagnostic criteria, no clear therapeutic goals have been established. For this reason, current 
glycemic threshold for non-critically ill, hospitalized patients are commonly accepted [95]. In this 
view, the treatment for SIDM and SIH should be started for fasting BG levels >140 mg/dL and 
post-prandial BG levels >180 mg/dL. The target of glycemic values should remain within the 140-
180 mg/dL range in the majority of patients, with levels <140 mg/dL only among selected patients, 
all this avoiding hypoglycemic crisis. 
The need for a specific management of SIH relies on data indicating that clinical outcomes worsen 
when glycemia is not adequately controlled. Among patients undergoing non-cardiac surgery, 
perioperative hyperglycemia has been associated with increased duration of hospitalization, risk of 
intensive care unit admission, and in-hospital complications (such as pneumonia, wound and 
systemic infections) as well as a strong association between mortality and glucose levels both 
before surgery and after surgery has been demonstrated [96]. Early hyperglycemia after 
glucocorticoid initiation has been found as a prominent risk factor for adverse outcome in patients 
with acute graft-versus-host disease [47]. Among patients with hematologic malignancies under 
high-dose corticosteroids, maximum glucose values represented a predictor of length of in-hospital 
stay, in particular among those without prior diabetes [29]. 
Considering differences in steroid posology, the therapeutic approaches to SIH and SIDM must 
always be tailored on the single patient. As previously described, taking into consideration 
pharmacokinetics and pharmacodynamics of different compounds as well as the pre-existing 
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glycemic profile and comorbidities is very important in order to start the best and less harmful 
hypoglycemic therapy. Accordingly, the choice among oral antidiabetic drugs or insulin is a critical 
step, which should consider also the duration of the corticosteroid therapy. 
Temporary steroidal therapy is a frequent schedule, characterized by a high initial dose then tapered 
with the improvement of the disease, so that glycemic decompensation, even if at a high degree, is 
limited in time. For this purpose, a hypoglycemic drug being potent, immediately acting, and with a 
long duration of action would be the better choice. Unfortunately, oral hypoglycemic drugs do not 
own all of these features and less useful. Especially for patients without a history of diabetes or with 
adequately controlled diabetes (e.g. pre-prandial glycemia <200 mg/dL), diet and lifestyle may be 
sufficient to achieve therapeutic goals [17]. 
 
5.1 Insulin secretagogues 
Some long-lasting sulfonylureas have been tested in kidney-transplanted patients giving partial 
results, as from one hand they induce insulin release contributing to glucose uptake by peripheral 
tissues, but on the other hand their narrow therapeutic window increase the risk for hypoglycemia 
[97]. Sulfonylureas could be better used for those patients administered with intermediate- or long-
acting steroids, even with two or more daily doses [98]. Recently, in a pilot study including patients 
with lymphoproliferative disorders requiring short courses of high-dose steroids, the treatment 
protocol started with gliclazide 80 mg and recommended to start insulin directly for glycemic 
values >324 mg/dL, showing to be safe with no episodes of hypoglycemia and no hospital 
admissions [51]. On the contrary, glinides own an immediate onset of action and a short half-life, 
better adapting to the post-prandial increase of glycemia induced by corticosteroids and providing a 
negligible risk of hypoglycemia [9]. 
 
5.2 Insulin sensitizer agents 
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Among insulin sensitizer agents, metformin can represent a good option because it directly 
counteracts glucocorticoid effects by enhancing insulin sensitivity and reducing gluconeogenesis. 
Its benefits include the low cost, its positive impact on weight, and a very low risk of hypoglycemia. 
Anyway, literature is scarce, including two studies [99, 100], as well as metformin can be 
contraindicated due to the underlying disease treated by steroids. Seelig et al recently displayed for 
the first time that preventive metformin treatment was effective in patients without diabetes under 
corticosteroid treatment with regard to glycemic control, also after adjustment for gender, total 
glucocorticoid dose, and HbA1c [100]. 
Thiazolidinediones enhance insulin action in skeletal muscle and adipose tissue, with scarce effect 
on insulin secretion. Even though used for long-time for SIDM [101, 102] due to their antagonistic 
effects on human metabolism in both adipose and muscle tissues compared to glucocorticoids [103], 
their side effects are not negligible, in particular water retention and the increased risk of bone 
fractures are shared with corticosteroids and can be therefore amplified. 
 
5.3 Incretins and glifozins 
DPP-4 inhibitors and glucagon-like peptide (GLP) 1 have been proven as effective in the control of 
hyperglycemia by enhancing the glucose-dependent release of insulin and peripheral glucose 
uptake, inhibiting glucagon secretion, and speeding gastric emptying [104, 105]. In particular, DPP-
4 inhibitors should be considered as first-choice treatment in light of their quick onset of action, 
their crucial role on post-prandial glycemia, and their limited risk of hypoglycemia. About this, 
sitagliptin has been described to improve some aspects of islet-cell function (e.g. fasting C-peptide 
and post-prandial glucagon secretion.), but cannot prevent glucocorticoid-induced derangement of 
post-prandial insulin response [106]. An ongoing study is analyzing the ability of sitagliptin on 
glucose metabolism in men with metabolic syndrome concurrently treated with prednisolone 30 mg 
daily (ClinicalTrials.gov Identifier: NCT00721552). In humans, the incretin effect is known to be 
reduced by glucocorticoids despite normal concentrations of active GLP1, suggesting that steroids 
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might alter GLP1-mediated activation of PKA [107]. Exenatide infusions have been described to 
prevent the acute diabetogenic effects of prednisolone in healthy volunteers [57]. Another 
mechanism by which GLP1 receptor agonist treatment can prevent glucocorticoid-induced 
hyperglycemia is the reduction of the gastric emptying rate, which is a typical pharmacological 
effect of this compound [108]. Exenatide administered subcutaneously has been reported to 
decrease BG levels in glucocorticoid-induced glucose intolerant mice, concurrently improving 
insulin resistance [109]. Therefore, suggested mechanisms for exenatide in SIDM may include 
restoration of the endogenous incretin effect and early insulin secretion, reduction in glucagon 
concentrations, and negligible risk of hypoglycemia [110]. 
To date, no studies are available for the new sodium-glucose cotransporter-2 inhibitors in the setting 
of SIDM. 
 
5.4 Insulin 
In all other situations, especially for glycemic values >200 mg/dL, insulin therapy is now 
considered the drug of choice [17]. Different schemes have been used, such as prandial insulin or 
schemes based on steroid dose and body mass index [111]. The prandial scheme is based on patient 
weight, total meal calories, and personal food pattern (e.g. snacks between meals or not). The initial 
dose is calculated at 0.1 U/kg per meal, then modified based on the glycemic response and the 
amount of supplementary insulin required to correct the pre-prandial hyperglycemia: 0.04 U/kg per 
meal when glycemia ranges between 200-300 mg/dL, 0.08 U/kg per meal for glycemia >300 
mg/dL. It is advisable to increase the initial dosage in case of repeated pre-prandial corrections 
[112]. Basal insulin should be used with high doses of glucocorticoids, mainly among patients with 
a prior history of diabetes and those with persistent fasting glucose >200 mg/dL. The starting dose 
is 0.1 U/kg before bedtime, with corrections when glycemia is persistently >300 mg/dL despite pre-
prandial corrections: 0.04 U/kg for glycemia between 300 and 400 mg/dL, 0.05 U/kg when 
glycemia is >400 mg/dL [112]. Another possibility, especially for those receiving a single daily 
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steroid dose in the morning, is to administer basal insulin in the morning in order to blunt the late 
afternoon/evening peak of intermediate-acting corticosteroids (prednisone and prednisolone) 
avoiding the dose increase of prandial insulin [113]. In case of multiple steroid doses, basal insulin 
should be reduced to 30% of the entire quantity of daily insulin with the remaining 70% to be 
divided across meals [37]. 
 
5.5 Management of SIH/SIDM in hospitalized patients 
With regard to the management of SIH in critically and non-critically ill patients, current guidelines 
give no precise indications, so that ongoing clinical practice is mainly driven by data coming from 
clinical studies and reappraisals made by reviews [37, 114, 115]. 
First of all, it is important to remember that the definition of hyperglycemia in hospitalized patients 
is based on BG levels >140 mg/dL and associated with poor outcomes (increased length of stay, 
infections) [37, 116]; accordingly, an admission HbA1c value ≥6.5% suggests that diabetes 
preceded hospitalization [117]. While not fully investigated in the setting of intensive care unit, SIH 
has been widely studied among hospitalized patients with cancer, who are typically treated in 
various settings, such as the internal medicine ward, the intensive care and palliative care units. 
Anyway, in a review by Brady et al investigating the management of SIH in cancer patients, all 
considered studies defined hyperglycemia for blood glycemic values >180 mg/dL, confirming that 
hyperglycemia, whatever the cause, is undertreated in hospitalized patients [118]. 
With concern to glucose monitoring, Pilkey et al [119] developed a guideline suggesting glucose 
monitoring twice a week before dinner, except for values between 180 and 360 mg/dl, for which the 
control is advised twice a day. In case of glucose values higher than 360 mg/dl, the start or the 
increase in insulin doses can be considered with a twice-a-day monitoring for two days. In patients 
without a history of diabetes, when hyperglycemia required treatment, the choice of drugs may 
range from oral antidiabetic agents, such as metformin, in combination with insulin until multiple 
daily doses of insulin [119]. For patients with known diabetes, the first step of the therapy included 
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diet in nearly one third of patients in two studies, while oral antidiabetic oral agents shared similar 
percentages (52% vs. 43) [118]. On the contrary, insulin was differently used, mainly before steroid 
therapy administration [120, 121]. In this regard, sliding scale regimens showed increased rates of 
hypoglycemia, confirming that basal-bolus regimen warranted a greater safety and could be 
considered the best way to manage SIH, especially when insulin is administered before GC 
administration [111, 121, 122]. 
In 2012, Umpierrez et al published a clinical practice guideline for the management of 
hyperglycemia in hospitalized patients [37]. Bedside glucose testing should be initiated for all 
patients receiving glucocorticoid therapy and can be discontinued in normoglycemic patients when 
glucose values are <140 mg/dl without insulin therapy for at least 24-48 h. Previously 
normoglycemic patients receiving corticosteroids were advised to be monitored for at least 24-48 h 
after the beginning of the therapy and those with glycemic values persistently >140 mg/dL require 
ongoing glucose testing while starting an appropriate therapy. Discontinuation of oral antidiabetic 
drugs is advised in favor of subcutaneous basal-bolus insulin regimen. The starting insulin dose and 
its posology has to be tailored on the basis of severity of hyperglycemia, type of corticosteroid drug, 
and duration of the treatment, although the suggested starting dosage is between 0.3 and 0.5 U/kg 
[37]. For patients on high-dose glucocorticoid therapy and in those with severe hyperglycemia not 
controlled by basal-bolus regimen, continuous insulin infusion might be taken into account as an 
alternative [37]. Similarly to Umpierrez et al, in 2013 the Associazione Medici Diabetologi (AMD), 
Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti (FADOI) and Società Italiana di 
Diabetologia (SID) published the Trialogue project aiming at helping internists in the management 
of hospitalised patients with hyperglycemia [115]. In acute patients with hyperglycemia under 
steroid treatment, insulin is the best therapy and should be administered according to the basal-
bolus regimen. This regimen has been shown to better control fasting BG values as well as to easily 
modify insulin boluses on the basis of hyperglycemic peaks, which typically are found in the second 
part of the day [115].More recently, the Standards of Medical Care in Diabetes stated that 
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glucocorticoid type and duration of treatment are pivotal elements to determine insulin regimens 
[117]. According to glucocorticoid half-life and peaks, intermediate-acting or long-acting insulin 
can be chosen. In accordance with other consensus statements, Standards conclude that generally 
adjustments based on anticipated changes in glucocorticoid dosages and glucose tests are critical to 
determine the insulin posology [117]. 
Actually, no indications are available for post-discharge management of patients with SIH/SIDM. 
In our opinion, current guidelines for post-discharge management of patients with diabetes can be 
considered [37, 115, 117]. In particular, a structured discharge plan should be organized for each 
patient, based on discharge setting (home with or without visiting nurse services, assisted living, 
rehabilitation, skilled nursing facilities, etc.) For self-sufficient patients discharged to home, the 
self-monitoring of BG and antidiabetic therapy will represent an important part of the management 
of SIH/SIDM with regard to type and duration of glucocorticoid therapy. An outpatient follow-up 
visit with a physician (primary care provider, endocrinologist, or diabetes educator) is advised for 
all patients within 1 month. In case of change in antidiabetic drugs or poor glycemic control after 
the discharge, an earlier appointment within 1-2 weeks represents to best strategy as well as 
frequent contact in order to avoid hyper- and hypoglycemia [117]. 
 
5.6 Transient hyperglycemia: what to do? 
Apart from considering what just abovementioned on the need to treat early SIH, it is worth 
discussing whether it is strictly necessary to treat transient SIH, especially in the hospital setting. 
The study by Popovich et al [123] analyzed the results of a randomized controlled trial involving 
patients with community-acquired pneumonia admitted to hospital and treated with 50 mg 
prednisone or placebo for 7 days [38]. As expected, patients under prednisone treatment presented 
with higher mean glucose levels and BG variability compared to patients in the placebo group, both 
for those with and without diabetes. In spite of hyperglycemia, the primary outcome (e.g. time to 
clinical stability) was not inferior for patients with diabetes and this was confirmed by a regression 
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analysis, supporting the concept that the presence of diabetes or SIH did not modify the benefit of 
prednisone therapy in this clinical situation [124]. Interestingly, the amount of insulin among 
patients with diabetes under prednisone was no greater than for those with diabetes on placebo; on 
the contrary, among patients without diabetes, those administered with prednisone received a larger 
amount of insulin compared to the placebo group [123]. Taking together all of these data, it seems 
that the question of hyperglycemia amongst the steroid-treated patients has not been completely 
solved. Although endocrinologists are correctly stressing on the glycemic control among 
hospitalized patients [125], it is widely known that this task is not always achieved due to the 
variable clinical status of patients, changing steroid doses, and especially the limited time of 
observation during the hospital stay. Actually, the evidence from literature about glycemic 
thresholds in hospitalized patients is controversial [126]. These aspects have been partially 
investigated [127, 128], mainly in the setting of the intensive care unit [129], but randomized 
clinical trials with a great number of patients coupling with a tight glycemic control are still lacking. 
Some information can be inferred from the Randomized Study of Basal-Bolus Insulin Therapy in 
the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 
2 Surgery) showing how basal bolus insulin regimen in a surgical cohort of patients suffering from 
diabetes warranted a better glucose control and consequently a lower rate of complications than 
sliding scale insulin [4]. Accordingly to the analysis by Popovich et al [123], it is unlikely to apply 
the results from RABBIT 2 Surgery to medical patients under corticosteroid treatment as well as a 
reflection is necessary about the real need to treat tightly transient SIH. For this purpose, large 
randomized clinical trials are welcomed to hopefully put an end to this important issue. 
 
6. Conclusions 
SIH implicates both clinical and economic problems due to its high prevalence, particularly in long-
term treated patients. The social impact of SIDM and SIH is linked to increased hospitalizations due 
to acute complications, whilst few data are available for chronic complications, which appear to be 
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underdiagnosed. Corticosteroid therapy is known to favor macrovascular complications in patients 
with diabetes, but not mortality. This different incidence depends on many factors, first of all 
referring to dose, route of administration, and duration of treatment of corticosteroids. The main 
caveat lies on the early and precise diagnosis of SIDM and/or identification of SIH, which must rely 
on 2-h post-prandial glycemia. To date, the following treatment should be reasoned and 
individualized accordingly to above proposed glycemic thresholds, choosing between antidiabetic 
oral drugs and insulin, even though the latter would have always to be preferred, especially for 
hospitalized patients. 
The diabetogenic effect of corticosteroids is referred to a negative impact on peripheral and central 
insulin sensitivity along with derangement on insulin secretion, causing most frequently post-
prandial hyperglycemia, especially in the late afternoon and in the evening. Starting from here, the 
therapeutic approach is aimed at limiting these dysfunctions in order to progressively reduce 
complications. Recently, incretin-based therapies, such as DPP-4 inhibitors and GLP1 receptor 
agonists, have become a new weapon in the armory of diabetologists at first and of clinicians taking 
care of patients with diabetes and SIDM or SIH then. In light of the action on meal-related insulin 
secretion and reduction of glucagon secretion, this new class of drugs directly target two important 
pathophysiological features of SIDM and SIH with a very low risk of hypoglycemia due to their 
glucose-dependent mechanism of action. 
SIDM and SIH are frequently encountered problems in the clinical practice, which need to be coped 
with on the basis of current indications. In this perspective, precise guidelines universally shared 
dealing with SIDM and SIH management would be welcomed in order to harmonize the treatment 
of these conditions overtaking single therapeutic strategies. 
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Figure 1. Mechanisms of glucocorticoid-induced hyperglycemia. Glucocorticoids own 
diabetogenic effects by impairing insulin sensitivity in liver, skeletal muscle, and adipose tissue as 
well as altering pancreatic β-cell function at different levels. Red arrows indicate negative effects, 
while green arrows stand for positive effects. 
Abbreviations: G6P: glucose-6-phosphatase; PEPK: phosphoenolpyruvate carboxykinase. 
 
Figure 2. Molecular pathways of glucocorticoid effects on glycemic and protein metabolism.  
Insulin can stimulate glucose uptake in cells via the translocation of glucose transporter (GLUT) 4 
from the intracellular compartment to the cell surface. After binding to its receptor, insulin triggers 
GLUT4 migration by the activation of cytosolic proteins (insulin receptor substrate-1, 
phosphatidylinositol 3 kinase, and Akt/protein kinase B. Glucose can then be processed by non-
oxidative pathways leading to glycogen synthesis, which is enhanced by insulin via the glycogen 
synthase kinase blocking glycogen synthase. Glucocorticoids are shown to impair insulin signaling 
cascade, resulting in reduced glucose uptake and glycogen synthesis. Moreover, the blunted insulin 
signaling is responsible for glucocorticoid-induced protein catabolism.  
Red, rounded arrows indicate inhibitory pathways. Red crosses show inhibitory effects by 
glucocorticoids. 
Abbreviations: GLUT4: glucose transporter 4; GS: glycogen synthase; GSK-3: glycogen synthase 
kinase-3; IGF-1: insulin-like growth factor 1; IRS-1: insulin receptor substrate-1; mTOR: 
mammalian target of rapamycin; MuRF-1: Muscle Ring Finger-1; P: phosphorylated; PI3K: 
phosphatidylinositol-3 kinase; PKB, protein kinase B; PP-1: protein phosphatase-1. 
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Table 1. Risk factors for steroid-induced diabetes mellitus 
 
Dosage and type of the drug 
Duration of treatment 
Posology (e.g. continuous vs. bolus treatment) 
Age ≥65 years old  
Male sex 
BMI* >25 kg/m
2
 
African American ethnic group 
eGFR° <40 mL/min/1,73 m
2
 
HbA1c
$
 ≥6.0% 
History of gestational diabetes 
Family history of diabetes mellitus 
Concomitant use of mycophenolate mofetil and calcineurin inhibitors 
Previous history of IFG
§
 and/or IGT
¶
 
 
Legend 
 
* BMI: body mass index 
° eGFR: estimated glomerular filtration rate 
$ HbA1c: glycated hemoglobin 
§ IFG: impaired fasting glucose 
¶ IGT: impaired glucose tolerance 
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Table 2. Most recent studies investigating steroid-induced hyperglycemia and/or diabetes mellitus 
 
Authors Design Diseases Patients Results 
Hematological diseases and cancer 
Aberer et al, 
2017 
[52] 
RCT GvHD 
10 patients under GC therapy assigned to 
either an automated decision support 
system (GlucoTab
®
) or conventional 
treatment followed-up for 6 months 
67.2% and 65.4% of glycemic values were within the 70-180 
mg/dL range for Glucotab
®
 and conventional treatment, 
respectively. Hypoglycemic values were less frequent for 
Glucotab
®
 group. 
Stauber et al, 
2017 [47] 
Retrospective 
study 
Acute GvHD 
104 patients receiving systemic GC 
therapy with glucose parameters assessed 
soon after initiation of GC. 
Early hypoglycemia was associated with shorter overall 
survival when considered across 3 different tertiles 
(p<0.0001). Patients under insulin treatment experienced an 
increased risk of death (HR 2.52, 95% CI 1.49-4.24; 
p=0.0005). A score based on early hyperglycemia and non-
response to GC within 7 days identified 3 risk groups, with 
patients carrying both risk factors showing the worst overall 
survival at 5 years (4.1% vs. 75.4% in patients with none, 
p=0.0002). 
Serrano et al, 
2017 [53] 
Prospective 
cohort study 
Hematological 
malignancies 
96 patients treated with high GC doses 
for at least 4 days. Patients diagnosed 
with GID were administered with NPH 
insulin, while those diagnosed with 
HGPD continued basal-bolus insulin 
regimen and were added NPH as GID 
protocol. 
30 patients developed HGPD and 66 GID with no difference 
in glucose control. Hypoglycemia was more frequent in the 
HGPD group. Accordingly, when comparing GID and 
HGPD, the highest insulin dose was 30 IU (IQR:18-45 IU) 
and 79.5 IU (IQR 43.5-109.5), respectively (p<0.001). 
Vidler et al, 
2017 [51] 
Prospective 
study 
Lymphoproliferative 
malignancies 
34 patients prescribed with high-dose GC 
checked capillary blood glucose before 
breakfast and dinner. 
17 patients developed SIH/SDM, while those with T2D 
developed SIH and 3 required insulin. Among non-diabetic 
patients, 8 developed SDM. Pre-treatment HbA1c was 
higher among patients developing SDM (p=0.002). 
Healy et al, 
2017 [29] 
Retrospective 
study 
Hematologic 
malignancies 
168 patients receiving systemic GC 
therapy for a 2-month period. 
Patients without diabetes under a GC dose equivalent to >12 
mg dexamethasone showed a greater increase in BG levels 
compared to a dose <12 mg (p=0.011). The maximum BG 
value predicted the length of hospital stay among patients 
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without diabetes (p=0.01) as well as with acute leukemia or 
stem cell transplantation (p=0.03 and 0.01, respectively). 
Gerards et al, 
2016 [39] 
Randomized 
crossover 
study 
Patients with SIH 
during antineoplastic 
chemotherapy 
26 patients with T2D or random BG level 
>216 mg/dL randomized to first SSI or 
first IMI as add-on to their routine 
diabetes medication on the days they 
used GC medication. 
By using CGM, patients in the IMI arm showed a higher 
proportion of BG values within the target range (70-180 
mg/dL) than SSI (p<0.001), whereas no severe 
hypoglycemic events have been registered. 
Lung diseases 
Torres et al, 
2015 [50] 
Multicenter, 
randomized, 
double-blind, 
placebo-
controlled 
trial 
Severe CAP 
120 hospitalized patients were 
randomized to either an IV bolus of 0.5 
mg/kg per 12 hours of 
methylprednisolone or placebo for 5 days 
within 36 hours from hospital admission. 
Hyperglycemia occurred in 11 patients in the 
methylprednisolone group and in 7 patients in the placebo 
group (p=0.34). 
Blum et al, 
2015 [38] 
Multicenter, 
randomized, 
double-blind, 
placebo-
controlled 
trial 
CAP 
785 hospitalized patients were randomly 
assigned to either prednisone 50 mg/day 
or placebo for 7 days within 24 hours 
from presentation. 
In the prednisone group, a higher rate of in-hospital 
hyperglycemia needing insulin treatment was registered 
when compared to the placebo group (19% vs. 11%, 
respectively). This association was then confirmed by the 
logistic regression analysis (OR 1·96, 95% 1·31-2·93; 
p=0·001). 
Tagarro et al, 
2017 [48] 
Multicenter, 
double-blind, 
parallel-
group, 
placebo-
controlled 
clinical trial 
Parapneumonic pleural 
effusion 
57 hospitalized children aged 1 month to 
14 years receiving either IV 
dexamethasone (0.25 mg/kg/dose) or 
placebo every 6 hours over a period of 48 
hours along with antibiotic therapy. 
Patients receiving dexamethasone experienced a shorter time 
to recovery (HR 1.95; 95% CI 1.10-3.45; p=0.021). The only 
difference between dexamethasone and placebo groups in 
terms of complications or adverse events was found for 
hyperglycemia (RR 2.5, 95% CI 1.2-5.5; p=0.02). 
Gerards et al, 
2018 [40] 
Double-blind 
RCT 
AECOPD 
46 hospitalized patients with known T2D 
under prednisone (at least 30 mg) were 
randomly assigned to dapagliflozin 10 
mg/day or placebo as add-on to their 
eventual routine diabetes medication. 
No difference in the time spent within the target range (3.9-
10 mmol/L), mean BG values, and incidence of 
hypoglycemic events between was found between groups. 
Immune diseases 
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Lv et al, 
2017 [54] 
Multicenter, 
double-blind, 
RCT 
IgA nephropathy 
262 patients randomized to oral 
methylprednisolone (0.6-0.8mg/kg/day) 
or placebo for 2 months, followed by a 
progressive weaning over 4-6 months. 
New-onset diabetes has been found in 2 patients in the GC 
group and in 3 patients in the placebo group, with no 
statistically significant difference. 
Radhakutty 
et al, 2016 
[45] 
Open, 
interventional 
and cross-
sectional 
study 
Rheumatoid arthritis 
36 subjects, of whom 18 subjects not 
administered any oral GC for at least 6 
months and 18 subjects taking a stable 
oral prednisolone dose of 4-10 mg/day 
for at least 6 months. The first group was 
evaluated before and after prednisolone 6 
mg/day for 7 days. 
Fasting BG was higher after acute prednisolone (p=0.02), 
while there was no difference for chronic administration. 
With regard to insulin resistance, Matsuda index was lower 
both after acute and chronic prednisolone (p=0.01 and 
p=0.04, respectively). Postprandial Aix75 as well as 
noradrenaline excretion were lower only after acute 
prednisolone (p≤0.001 and p=0.02, respectively). 
Tanaka et al, 
2018 [49] 
Case report 
Thyroid 
ophthalmopathy 
5 patients administered 
methylprednisolone pulse therapy 
developing SDM were treated alternately 
with mitiglinide (30 mg/day) and 
repaglinide (1.5 mg/day) during the 
second or third pulse therapy. All patients 
were assessed by CGM. 
BG levels before lunch and dinner showed a better glycemic 
control with repaglinide (p=0.043 for both vs. mitiglinide). 
Orthopedic disorders 
Kim et al, 
2015 [41] 
Prospective 
trial 
Disorders of the hand or 
wrist requiring an 
injection of 
corticosteroid 
25 adult, diabetic patients administered 
with an injection of 1 mL with 10 mg of 
triamcinolone acetonide mixed with 1 mL 
of 1% lidocaine with no epinephrine. 
20 patients showed an increase in their BG from baseline, 
which returned to normality after 5 days (p=0.005). Patients 
with HbA1c ≥7% were found with higher BG values 
(p=0.003) lasting for a longer time than those with HbA1c 
<7% (p=0.0004). A correlation between HbA1c and 
increased BG levels from day 1 to 4 was found (p=0.0003 
for day 1, p<0.0001 for other days). 
Posttransplantion complications 
Mourad et al, 
2017 [43] 
Multicenter, 
prospectively 
randomized, 
open-label 
study 
PTDM 
1166 patients undergoing kidney 
transplantation treated with prolonged-
release tacrolimus, basiliximab, MM, and 
1 bolus of intraoperative corticosteroids. 
Patients in arm 1 received tapered GC, 
By a Kaplan-Meier analysis, the incidence of PTDM after 24 
weeks was similar for both arms, with no statistically 
significant difference (p=0.579). 
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stopped after 10 days, while patients in 
arm 2 received no steroids after the 
intraoperative bolus. 
Pirsch et al, 
2015 [44] 
Prospective, 
double-blind 
RCT 
PTDM 
277 patients following kidney 
transplantation who early withdrew GC 
were investigated to evaluate whether GC 
avoidance could reduce PTDM risk. 
By evaluating different PTDM definitions, only age, but not  
GC use, was a significant risk factor for PTDM for more 
than one definition (HR ranging from 1.02 to 1.03 and with 
p ranging from <0.001 up to 0.04). 
Miscellaneous 
Radhakutty 
et al, 2017 
[46] 
Open-label 
stratified 
RCT 
Acute medical 
condition not further 
specified 
50 consecutive hospitalized patients 
treated under oral prednisolone ≥20 
mg/day as a single morning dose received 
a total daily dose of insulin of 0.5 IU/kg 
(isophane plus aspart in one group and 
glargine plus aspart in the other group. 
On day 1, no significant differences in percentage of time 
outside a target glucose range of 72-180 mg/dL, mean daily 
glucose, and glucose <72 mg/dL was registered in both 
groups. 
Lakhani et al, 
2017 [42] 
Randomized, 
open-labeled, 
parallel arm 
trial 
Any medical condition 
67 patients randomized to control group 
(standard basal-bolus insulin) or the 
experimental one (“correctional insulin” 
matching the glycemic profile of the GC 
with or without background basal-bolus 
insulin). 
Mean BG values were lower in the experimental group (p= 
0.0001), as confirmed by all parameters of glycemic 
variability (p=0.0001). Hypoglycemia event rates was low in 
both groups, but statistically significant only for severe 
events in the experimental group (p=0.0001). 
 
Legend 
AECOPD: acute exacerbation of chronic obstructive pulmonary disease. AI: augmentation index. AIx75: augmentation index normalized for a heart 
rate of 75 beats per minute. AUC: area under the curve. BG: blood glucose. CAP: community-acquired pneumonia. CGM: continuous glucose 
monitoring. CI: confidence interval. GC: glucocorticoid. GID: glucocorticoid-induced diabetes. GvHD: graft-versus-host-disease. HbA1c: glycated 
hemoglobin. HGPD: hyperglycemia in a patient with previous diagnosed diabetes. HR: hazard ratio. IMI: intermediate-acting insulin. IQR: 
interquartile range. IU: international unit. IV: intravenous. MMF: mycophenolate mofetil. OR: odds ratio. PTDM: posttransplantation diabetes 
mellitus. RCT: randomized clinical trial. NPH: neutral protamine Hagedorn. RR: risk ratio. SDM: steroid-induced diabetes mellitus. SIH: steroid-
induced hyperglycemia. SSI: sliding scale insulin. T2D: type 2 diabetes.
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Table 3. Half-life of different glucocorticoids 
 
Drug  Half-life (h) 
Short-acting 
  
Cortisone  
8-12 
Hydrocortisone  
  
Intermediate-acting 
  
12-16 
Prednisolone  
Prednisone  
Methylprednisolone  
  
 
  
12-24 
Deflazacort  
Fludrocortisone  
Triamcinolone  
  
Long-acting 
  
Betamethasone  
20-36 
Dexamethasone  
  
 
 
 
